AT ATAI AtaiBeckley Inc. Loading... : Bullish and Bearish Analyst Opinions

Reports ATAI acquisition by Lilly for ~$3.8B, validating the company's mission. No directional view from speaker.

Comments on clinical trials validating psychedelics for TRD/PTSD. No directional view from speaker.

Cathie Wood congratulates Christian Angermayer for his long-standing mission to reactivate psychedelics, referencing ATAI's role in clinical trials for treatment-resistant depression and PTSD.

US pre-market movers show mixed sector action with TSM down on capex hike despite strong results, UAL lower on light guidance, JBHT up on earnings beat, ATAI surging on LLY acquisition, UNH and ABT rising on strong earnings and outlook, DSGR jumping on buyout, and LULU falling on a Truist downgrade.

Premarket movers report shows mixed Mag 7 stocks, ATAI surging on Eli Lilly acquisition talks, GE and UAL declining on earnings, and UNH rising on raised outlook with peer insurers following.

Eli Lilly announces definitive agreement to acquire AtaiBeckley for its pipeline of neuroplastogen therapies targeting treatment-resistant depression.

Co-mentioned alongside Lilly deal news as a potential M&A target in biotech; no speaker thesis or position disclosed.

Author endorses psychedelic stocks as a good sector to be long with massive upside potential, but does not state a personal position in the specific tickers.

The author claims "Psychedelics getting Trump sign off," implying favorable regulatory changes. If regulatory approval accelerates, companies like ATAI (Atai Life Sciences) working on psychedelic therapies could see increased investor interest and valuation. The author is holding and believes the uptrend will continue, making it a long opportunity based on policy sentiment. The post provides zero evidence; political news may be misinterpreted or irrelevant. Regulatory paths are long and uncertain. Stock is highly volatile and speculative.

Trump's EO directs FDA to accelerate psychedelic reviews; ATAI's lead asset BPL-003 has Breakthrough Therapy Designation and is about to start Phase 3. The company could receive a national priority voucher next week, drastically compressing the approval timeline and attracting institutional capital. Regulatory risk has plummeted, Phase 3 is imminent, and the stock is poised for a re-rating with massive analyst upside. Phase 3 trial failure, voucher not awarded, broader market sell-off affecting speculative biotech.

AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg $JPM $JEF $ATAI #stockmarket #trading #investing https://t.co/hBoN7itUac

First Squawk (@FirstSquawk) ATAI BECKLEY IS WORKING WITH ADVISERS TO EXPLORE OPTIONS FOR ITS FLAGSHIP PSYCHEDELIC DRUG CANDIDATE, ACCORDING TO PEOPLE FAMILIAR WITH THE MATTER. Tweet Link

AtaiBeckley is working with advisers to explore options for its flagship psychedelic drug candidate, according to people familiar with the matter. https://t.co/e3s7pkF6Mj